

Author index

- Aga, H., see Kunikata, T. (410) 93
Aizawa, H., see Takahashi, N. (410) 61
Anderson, G.M., see Veenstra-VanderWeele, J. (410) 165
Arinami, T., Ishiguro, H. and Onaivi, E.S.
 Polymorphisms in genes involved in neurotransmission in relation to smoking (410) 215

Beleta, J., see Bou, J. (410) 33
Belmaker, R.H., see Ebstein, R.P. (410) 205
Benjamin, J., see Ebstein, R.P. (410) 205
Berkó, A., see Pávó, I. (410) 101
Bou, J., Domènech, T., Puig, J., Heredia, A., Gras, J., Fernández-Forner, D., Beleta, J. and Palacios, J.M.
 Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine (410) 33
Bou, J., see Gras, J. (410) 43
Bouchard, C., see Ravussin, E. (410) 131
Buckle, C.E., see Wong, A.H.C. (410) 183

Cardelús, I., see Gras, J. (410) 53
Ceballos, G., see Zenteno-Savin, T. (410) 15
Cook Jr., E.H., see Veenstra-VanderWeele, J. (410) 165
Cox, D.A., see Pávó, I. (410) 101

Danser, A.H.J. and Schunkert, H.
 Renin–angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases (410) 303
De Boer, A., see Maitland-van der Zee, A.H. (410) 121
Del Carmen Recio, M., see Huguet, A.-I. (410) 69
Domènech, T., see Bou, J. (410) 33
Dreon, D.M., see Peroutka, S.J. (410) 161

Ebstein, R.P., Benjamin, J. and Belmaker, R.H.
 Personality and polymorphisms of genes involved in aminergic neurotransmission (410) 205
Escande, D.
 Pharmacogenetics of cardiac K⁺ channels (410) 281

Fernández, A.G., see Gras, J. (410) 43
Fernández-Forner, D., see Bou, J. (410) 33
Franke, P., see Lichtermann, D. (410) 269
Fukuyama, S., see Takahashi, N. (410) 61

Giner, R.-M., see Huguet, A.-I. (410) 69
Gras, J., Bou, J., Llenas, J., Fernández, A.G. and Palacios, J.M.
 Functional profile of almotriptan in animal models predictive of antimigraine activity (410) 43
Gras, J., Cardelús, I., Llenas, J. and Palacios, J.M.
 Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine (410) 53
Gras, J., see Bou, J. (410) 33
Grip, O., Janciauskiene, S. and Lindgren, S.
 Pravastatin down-regulates inflammatory mediators in human monocytes in vitro (410) 83

Hara, N., see Takahashi, N. (410) 61
Hebebrand, J., see Hinney, A. (410) 147
Heredia, A., see Bou, J. (410) 33
Hinney, A., Remschmidt, H. and Hebebrand, J.
 Candidate gene polymorphisms in eating disorders (410) 147
Huguet, A.-I., Del Carmen Recio, M., Mániz, S., Giner, R.-M. and Ríos, J.-L.
 Effect of triterpenoids on the inflammation induced by protein kinase C activators, neuronally acting irritants and other agents (410) 69

Ikeda, M., see Kunikata, T. (410) 93
Inoue, H., see Takahashi, N. (410) 61
Ishiguro, H., see Arinami, T. (410) 215
Itoh, T., see Suzuki, Y. (410) 7
Iwaki, K., see Kunikata, T. (410) 93

Janciauskiene, S., see Grip, O. (410) 83

Kagami, M., see Shimokawa, T. (410) 1
Kajikuri, J., see Suzuki, Y. (410) 7
Kato, M., see Shimokawa, T. (410) 1
Katoh, M., see Shimokawa, T. (410) 1
Kawanishi, Y., Tachikawa, H. and Suzuki, T.
 Pharmacogenomics and schizophrenia (410) 227
Kreek, M.J., see LaForge, K.S. (410) 249
Kunikata, T., Tatefuji, T., Aga, H., Iwaki, K., Ikeda, M. and Kurimoto, M.
 Indirubin inhibits inflammatory reactions in delayed-type hypersensitivity (410) 93
Kurimoto, M., see Kunikata, T. (410) 93
Kurosaki, E., see Shimokawa, T. (410) 1

LaForge, K.S., Yuferov, V. and Kreek, M.J.
 Opioid receptor and peptide gene polymorphisms: potential implications for addictions (410) 249
Laher, I., see Lui, A.H. (410) 25
László, F., see Pávó, I. (410) 101
László, F.A., see Pávó, I. (410) 101
Leufkens, H.G.M., see Maitland-van der Zee, A.H. (410) 121
Lichtermann, D., Franke, P., Maier, W. and Rao, M.L.
 Pharmacogenomics and addiction to opiates (410) 269
Lindgren, S., see Grip, O. (410) 83
Llenas, J., see Gras, J. (410) 43
Llenas, J., see Gras, J. (410) 53
Lui, A.H., McManus, B.M. and Laher, I.
 Endothelial and myogenic regulation of coronary artery tone in the mouse (410) 25

Maier, W., see Lichtermann, D. (410) 269
Maitland-van der Zee, A.H., De Boer, A. and Leufkens, H.G.M.
 The interface between pharmacoepidemiology and pharmacogenetics (410) 121
Mániz, S., see Huguet, A.-I. (410) 69
McManus, B.M., see Lui, A.H. (410) 25

- Morschl, É., see Pávó, I. (410) 101
Mullan, M., see Town, T. (410) 243
- Nebert, D.W.
Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics (410) 107
Nemcsik, J., see Pávó, I. (410) 101
Nishima, S., see Takahashi, N. (410) 61
- Onaivi, E.S., see Arinami, T. (410) 215
- Palacios, J.M., see Bou, J. (410) 33
Palacios, J.M., see Gras, J. (410) 43
Palacios, J.M., see Gras, J. (410) 53
Pávó, I., László, F., Morschl, É., Nemcsik, J., Berkó, A., Cox, D.A. and László, F.A.
Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats (410) 101
Peroutka, S.J. and Dreon, D.M.
The value of genotyping for apolipoprotein E alleles in relation to vitamin E supplementation (410) 161
Puig, J., see Bou, J. (410) 33
- Rao, M.L., see Lichtermann, D. (410) 269
Ravussin, E. and Bouchard, C.
Human genomics and obesity: finding appropriate drug targets (410) 131
Remschmidt, H., see Hinney, A. (410) 147
Ríos, J.-L., see Huguet, A.-I. (410) 69
Rubio, R., see Zenteno-Savin, T. (410) 15
- Sada-Ovalle, I., see Zenteno-Savin, T. (410) 15
Schinka, J., see Town, T. (410) 243
Schunkert, H., see Danser, A.H.J. (410) 303
Shibasaki, M., see Shimokawa, T. (410) 1
Shimokawa, T., Kagami, M., Kato, M., Kurosaki, E., Shibasaki, M. and Katoh, M.
Effect of YM-126414 on glucose uptake and redistribution of glucose transporter isotype 4 in muscle cells (410) 1
- Staessen, J.A., see Wang, J.-G. (410) 289
Suzuki, T., see Kawanishi, Y. (410) 227
Suzuki, Y., Yamamoto, T., Suzumori, K., Kajikuri, J. and Itoh, T.
Modified histamine-induced NO-mediated relaxation in resistance arteries in pre-eclampsia (410) 7
Suzumori, K., see Suzuki, Y. (410) 7
- Tachikawa, H., see Kawanishi, Y. (410) 227
Takahashi, N., Aizawa, H., Fukuyama, S., Inoue, H., Nishima, S. and Hara, N.
Thapsigargin, a Ca^{2+} -ATPase inhibitor, relaxes guinea pig tracheal smooth muscle by producing epithelium-dependent relaxing factors (410) 61
Tan, J., see Town, T. (410) 243
Tatefuji, T., see Kunikata, T. (410) 93
Town, T., Schinka, J., Tan, J. and Mullan, M.
The opioid receptor system and alcoholism: a genetic perspective (410) 243
- Van Tol, H.H.M., see Wong, A.H.C. (410) 183
Veenstra-VanderWeele, J., Anderson, G.M. and Cook Jr., E.H.
Pharmacogenetics and the serotonin system: initial studies and future directions (410) 165
- Wang, J.-G. and Staessen, J.A.
Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease (410) 289
Wong, A.H.C., Buckle, C.E. and Van Tol, H.H.M.
Polymorphisms in dopamine receptors: what do they tell us? (410) 183
- Yamamoto, T., see Suzuki, Y. (410) 7
Yuferov, V., see LaForge, K.S. (410) 249
- Zenteno-Savin, T., Sada-Ovalle, I., Ceballos, G. and Rubio, R.
Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors (410) 15